A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT05706506

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05706506
  • EudraCT 2022-002708-18
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05706506. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-08 (actual); primary completion 2023-10-31 (actual). Results posted on 2024-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Tirzepatide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05706506
Content hash
6be8f237d0fa8a011b7c08d3840f8ae511a6dcda92ba501e819c4716d98159ac